2Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project[J]. Ann Oncol, 1998, 9(7): 717-720.
3Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25): 4124-4130.
4Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-586.
5Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification[J]. Ann Oncol, 2004, 15(10): 1467-1475.
6Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group[J]. Blood, 2010, 116(18): 3418-3425.
7Chen AI, McMillan A, Negrin RS, et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience[J]. Biol Blood Marrow Transplant, 2008, 14(7): 741-747.
8Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study[J]. J Clin Oncol, 2009, 27(1): 106-113.
10Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study[J]. Bone Marrow Transplant, 2007, 40(5): 443-450.
